These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2330861)
1. Hemodynamic effects of intravenous procainamide during ventricular tachycardia. Sharma AD; Purves P; Yee R; Klein G; Jablonsky G; Kostuk WJ Am Heart J; 1990 May; 119(5):1034-41. PubMed ID: 2330861 [TBL] [Abstract][Full Text] [Related]
2. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia. Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498 [TBL] [Abstract][Full Text] [Related]
3. Predicting ventricular tachycardia cycle length after procainamide by assessing cycle length-dependent changes in paced QRS duration. Marchlinski FE; Buxton AE; Josephson ME; Schmitt C Circulation; 1989 Jan; 79(1):39-46. PubMed ID: 2910546 [TBL] [Abstract][Full Text] [Related]
4. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans. Kidwell GA; Greenspon AJ; Greenberg RM; Volosin KJ Circulation; 1993 Jan; 87(1):118-25. PubMed ID: 8418998 [TBL] [Abstract][Full Text] [Related]
5. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983 [TBL] [Abstract][Full Text] [Related]
6. Effect of procainamide on induced ventricular tachycardia. Engel TR; del Gonzalez A; Meister SG; Franki WS Clin Pharmacol Ther; 1978 Sep; 24(3):274-82. PubMed ID: 688720 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of procainamide on ventricular tachycardia: relation to prolongation of refractoriness and slowing of conduction. Furukawa T; Rozanski JJ; Moroe K; Gosselin AJ; Lister JW Am Heart J; 1989 Oct; 118(4):702-8. PubMed ID: 2801477 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy. Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899 [TBL] [Abstract][Full Text] [Related]
9. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction. Kus T; Costi P; Dubuc M; Shenasa M Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538 [TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of combined treatment with lignocaine, procainamide and practolol in acute myocardial infarction. Nordlander R; Nyquist O Cardiology; 1980; 66(1):27-42. PubMed ID: 7388852 [TBL] [Abstract][Full Text] [Related]
11. Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. Marchlinski FE; Buxton AE; Miller JM; Vassallo JA; Flores BT; Josephson ME Circulation; 1986 Nov; 74(5):1037-43. PubMed ID: 3769163 [TBL] [Abstract][Full Text] [Related]
12. A comparison of sotalol and procainamide in symptomatic ventricular tachycardia. Jordaens LJ; Colardyn F; Clement DL Cardiovasc Drugs Ther; 1989 Apr; 3(2):155-61. PubMed ID: 2487531 [TBL] [Abstract][Full Text] [Related]
13. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Somberg JC; Butler B; Flowers D; Tepper D; Maguire W; Willens H; Keren G; Miura D Am J Cardiol; 1984 Aug; 54(4):49B-54B. PubMed ID: 6465047 [TBL] [Abstract][Full Text] [Related]
14. The role of combination therapy with mexiletine and procainamide in patients with inducible sustained ventricular tachycardia refractory to intravenous procainamide. Widerhorn J; Sager PT; Rahimtoola SH; Bhandari AK Pacing Clin Electrophysiol; 1991 Mar; 14(3):420-6. PubMed ID: 1708872 [TBL] [Abstract][Full Text] [Related]
15. Electrophysiologic and clinical factors influencing response to class IA antiarrhythmic agents in patients with inducible sustained monomorphic ventricular tachycardia. Gold RL; Haffajee CI; Alpert JS Am Heart J; 1986 Jul; 112(1):9-13. PubMed ID: 3728294 [TBL] [Abstract][Full Text] [Related]
17. Procainamide, disopyramide and quinidine: discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia. Wyse DG; Mitchell LB; Duff HJ J Am Coll Cardiol; 1987 Apr; 9(4):882-9. PubMed ID: 3558987 [TBL] [Abstract][Full Text] [Related]
18. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias. Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852 [TBL] [Abstract][Full Text] [Related]
19. Comparison of individual and combined effects of procainamide and amiodarone in patients with sustained ventricular tachyarrhythmias. Marchlinski FE; Buxton AE; Kindwall KE; Miller JM; Rosenthal ME; Gottlieb CD; Bloom RB; Josephson ME Circulation; 1988 Sep; 78(3):583-91. PubMed ID: 3409498 [TBL] [Abstract][Full Text] [Related]
20. Beta blockers in combination with class I antiarrhythmic agents. Deedwania PC; Olukotun AY; Kupersmith J; Jenkins P; Golden P Am J Cardiol; 1987 Aug; 60(6):21D-26D. PubMed ID: 2442991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]